OxThera   Report issue

For profit Phase 2 Phase 3
Founded: Stockholm Sweden (2005)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2007
NCT00638703
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

OxThera

Active Ingredients

Drugs in Phase 3 Trials (2)

oxalobacter formigenes (4 trials)

oxalobacter formigenes hc-1 (2 trials)

Drugs in Phase 2 Trials (1)

oxalate decarboxylase (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hyperoxaluria, Primary (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 3